Wondering why we have a brand new look? We have exciting news - HealthSpotlight has merged with and rebranded as AllMyHealth.
Our shared commitment to supporting rare disease communities with trusted resources and advocacy remains as strong as ever - now under a unified name that reflects our patient-first values.
We collaborate with patient support groups to create advocacy materials and amplify community news and events.
Recent advancements in understanding Mantle Cell Lymphoma (MCL) have highlighted its molecular diversity, which correlates with varying patient outcomes. Ip et al. (2025) note that despite updates to prognostic risk scores, they still lack key high-risk features like TP53 mutations and complex karyotypes. These features are critical as they are associated with rapid disease progression and lower survival rates.
The use of next-generation sequencing (NGS) has improved the identification of genetic alterations that help in prognostication and disease monitoring. This has led to more personalized treatment approaches, including novel therapies targeting specific disease mechanisms. These therapies, along with traditional chemoimmunotherapy and stem cell transplantation, have expanded treatment options and improved survival for those with relapsed or refractory MCL. Ip et al. emphasize that further research into MCL's biological heterogeneity is essential for enhancing patient management and treatment.
More Info 
Add to Calendar